Pharsight

Drugs that contain Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate

1. Stribild patents expiration

STRIBILD's oppositions filed in EPO
STRIBILD IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(2 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(2 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(2 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5814639 GILEAD SCIENCES INC Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5814639

(Pediatric)

GILEAD SCIENCES INC Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US5914331 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

US5977089 GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US6043230 GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5935946 GILEAD SCIENCES INC Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US5922695 GILEAD SCIENCES INC Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5914331

(Pediatric)

GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US5922695

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jan, 2018

(6 years ago)

US5977089

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US6043230

(Pediatric)

GILEAD SCIENCES INC Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US5935946

(Pediatric)

GILEAD SCIENCES INC Nucleotide analog composition and synthesis method
Jan, 2018

(6 years ago)

US6642245 GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6703396 GILEAD SCIENCES INC Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

US6642245

(Pediatric)

GILEAD SCIENCES INC Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(3 years ago)

US6703396

(Pediatric)

GILEAD SCIENCES INC Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(4 months ago)

US8716264

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jul, 2024

(a month from now)

US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(2 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(2 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(2 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(5 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(5 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(5 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(6 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(8 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-704) Dec 17, 2017
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Patient Population(NPP) Jan 27, 2020
New Product(NP) Aug 27, 2015

NCE-1 date: 27 August, 2016

Market Authorisation Date: 27 August, 2012

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage

STRIBILD family patents

Family Patents